An overview of adapalene and benzoyl peroxide once-daily topical gel as a therapeutic option for acne

Veronica K. Emmerich; Caitlin G. Purvis; Steven R. Feldman

doi:10.1080/14656566.2021.1939678

An overview of adapalene and benzoyl peroxide once-daily topical gel as a therapeutic option for acne

Veronica K. Emmerich^*
, Caitlin G. Purvis
, Steven R. Feldman

^*Kontaktforfatter

KI, OUH, Forskningsenhed for Dermatovenerologi og allergi (Odense)

Wake Forest University

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › peer review

1249 Downloads (Pure)

Abstract

Introduction: Acne vulgaris is the most common skin condition worldwide, and it is associated with substantial psychological comorbidity. Topical therapies–including retinoids, antibiotics, and benzoyl peroxide–are the cornerstones of treatment for patients with acne. The main barriers to care in the treatment of acne are poor adherence to therapy and lack of tolerability. Areas covered: Herein, the authors review the safety and efficacy of adapalene/benzoyl peroxide combination gel (0.1%/2.5% and 0.3%/2.5%), as well as its specific mechanisms of action that target acne vulgaris. The authors also offer an expert opinion on the use of adapalene/benzoyl peroxide gel compared with other topical therapies. Expert opinion: Adapalene/benzoyl peroxide gel is safe and highly effective in the treatment of acne vulgaris. Its efficacy, tolerability, and ease-of-use are superior to other topical acne therapies, and its use does not contribute to antibiotic resistance. However, the cost of adapalene/benzoyl peroxide gel and lack of available generics may prohibit its use.

Originalsprog	Engelsk
Tidsskrift	Expert Opinion on Pharmacotherapy
Vol/bind	22
Udgave nummer	13
Sider (fra-til)	1661-1667
ISSN	1465-6566
DOI	https://doi.org/10.1080/14656566.2021.1939678
Status	Udgivet - sep. 2021

Bibliografisk note

Funding Information:
Over the past 5 years, S Feldman has received research grants, speaking and/or consulting support from AbbVie, Amgen, Janssen Pharmaceuticals, Alvotech, vTv Therapeutics, Bristol-Myers Squibb, Samsung, Pfizer, Sanofi, Regeneron, Boehringer Ingelheim, Dermavant, Galderma, Arcutis, Novartis, UCB Pharma, Helsinn, Sun Pharmaceuticals Industries Ltd., Almirall, Leo Pharma, Mylan, Merck & Co, Pierre Fabre, Promius, Foamix, Forte, TwoXar, Arena Pharmaceuticals Ltd, Menlo, Ortho Pharmaceutical, Mayne Pharma, Sienna Biopharmaceuticals, Avva, Alcimed, and Qurient. He is founder and majority owner of www.DrScore.com and founder and part owner of Causa Research. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

Finansiering

Over the past 5 years, S Feldman has received research grants, speaking and/or consulting support from AbbVie, Amgen, Janssen Pharmaceuticals, Alvotech, vTv Therapeutics, Bristol-Myers Squibb, Samsung, Pfizer, Sanofi, Regeneron, Boehringer Ingelheim, Dermavant, Galderma, Arcutis, Novartis, UCB Pharma, Helsinn, Sun Pharmaceuticals Industries Ltd., Almirall, Leo Pharma, Mylan, Merck & Co, Pierre Fabre, Promius, Foamix, Forte, TwoXar, Arena Pharmaceuticals Ltd, Menlo, Ortho Pharmaceutical, Mayne Pharma, Sienna Biopharmaceuticals, Avva, Alcimed, and Qurient. He is founder and majority owner of www.DrScore.com and founder and part owner of Causa Research. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

Dokumenter og links

10.1080/14656566.2021.1939678

Open Access VersionAccepteret manuskript, 626 KBLicens: CC BY-NC

SDU link

Tjek adgangen til materialet i Syddansk Universitetsbiblioteks søgemaskine

Citationsformater

@article{d51a57818e854a60a5a4a3b1adbaf83e,

title = "An overview of adapalene and benzoyl peroxide once-daily topical gel as a therapeutic option for acne",

abstract = "Introduction: Acne vulgaris is the most common skin condition worldwide, and it is associated with substantial psychological comorbidity. Topical therapies–including retinoids, antibiotics, and benzoyl peroxide–are the cornerstones of treatment for patients with acne. The main barriers to care in the treatment of acne are poor adherence to therapy and lack of tolerability. Areas covered: Herein, the authors review the safety and efficacy of adapalene/benzoyl peroxide combination gel (0.1\%/2.5\% and 0.3\%/2.5\%), as well as its specific mechanisms of action that target acne vulgaris. The authors also offer an expert opinion on the use of adapalene/benzoyl peroxide gel compared with other topical therapies. Expert opinion: Adapalene/benzoyl peroxide gel is safe and highly effective in the treatment of acne vulgaris. Its efficacy, tolerability, and ease-of-use are superior to other topical acne therapies, and its use does not contribute to antibiotic resistance. However, the cost of adapalene/benzoyl peroxide gel and lack of available generics may prohibit its use.",

keywords = "Acne vulgaris, adapalene, benzoyl peroxide, combination therapy, retinoids, topical, Adapalene, Humans, Treatment Outcome, Dermatologic Agents/therapeutic use, Naphthalenes, Benzoyl Peroxide, Acne Vulgaris/drug therapy, Drug Combinations",

author = "Emmerich, \{Veronica K.\} and Purvis, \{Caitlin G.\} and Feldman, \{Steven R.\}",

note = "Funding Information: Over the past 5 years, S Feldman has received research grants, speaking and/or consulting support from AbbVie, Amgen, Janssen Pharmaceuticals, Alvotech, vTv Therapeutics, Bristol-Myers Squibb, Samsung, Pfizer, Sanofi, Regeneron, Boehringer Ingelheim, Dermavant, Galderma, Arcutis, Novartis, UCB Pharma, Helsinn, Sun Pharmaceuticals Industries Ltd., Almirall, Leo Pharma, Mylan, Merck \& Co, Pierre Fabre, Promius, Foamix, Forte, TwoXar, Arena Pharmaceuticals Ltd, Menlo, Ortho Pharmaceutical, Mayne Pharma, Sienna Biopharmaceuticals, Avva, Alcimed, and Qurient. He is founder and majority owner of www.DrScore.com and founder and part owner of Causa Research. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed. ",

year = "2021",

month = sep,

doi = "10.1080/14656566.2021.1939678",

language = "English",

volume = "22",

pages = "1661--1667",

journal = "Expert Opinion on Pharmacotherapy",

issn = "1465-6566",

publisher = "Taylor \& Francis",

number = "13",

}

TY - JOUR

T1 - An overview of adapalene and benzoyl peroxide once-daily topical gel as a therapeutic option for acne

AU - Emmerich, Veronica K.

AU - Purvis, Caitlin G.

AU - Feldman, Steven R.

N1 - Funding Information: Over the past 5 years, S Feldman has received research grants, speaking and/or consulting support from AbbVie, Amgen, Janssen Pharmaceuticals, Alvotech, vTv Therapeutics, Bristol-Myers Squibb, Samsung, Pfizer, Sanofi, Regeneron, Boehringer Ingelheim, Dermavant, Galderma, Arcutis, Novartis, UCB Pharma, Helsinn, Sun Pharmaceuticals Industries Ltd., Almirall, Leo Pharma, Mylan, Merck & Co, Pierre Fabre, Promius, Foamix, Forte, TwoXar, Arena Pharmaceuticals Ltd, Menlo, Ortho Pharmaceutical, Mayne Pharma, Sienna Biopharmaceuticals, Avva, Alcimed, and Qurient. He is founder and majority owner of www.DrScore.com and founder and part owner of Causa Research. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

PY - 2021/9

Y1 - 2021/9

N2 - Introduction: Acne vulgaris is the most common skin condition worldwide, and it is associated with substantial psychological comorbidity. Topical therapies–including retinoids, antibiotics, and benzoyl peroxide–are the cornerstones of treatment for patients with acne. The main barriers to care in the treatment of acne are poor adherence to therapy and lack of tolerability. Areas covered: Herein, the authors review the safety and efficacy of adapalene/benzoyl peroxide combination gel (0.1%/2.5% and 0.3%/2.5%), as well as its specific mechanisms of action that target acne vulgaris. The authors also offer an expert opinion on the use of adapalene/benzoyl peroxide gel compared with other topical therapies. Expert opinion: Adapalene/benzoyl peroxide gel is safe and highly effective in the treatment of acne vulgaris. Its efficacy, tolerability, and ease-of-use are superior to other topical acne therapies, and its use does not contribute to antibiotic resistance. However, the cost of adapalene/benzoyl peroxide gel and lack of available generics may prohibit its use.

AB - Introduction: Acne vulgaris is the most common skin condition worldwide, and it is associated with substantial psychological comorbidity. Topical therapies–including retinoids, antibiotics, and benzoyl peroxide–are the cornerstones of treatment for patients with acne. The main barriers to care in the treatment of acne are poor adherence to therapy and lack of tolerability. Areas covered: Herein, the authors review the safety and efficacy of adapalene/benzoyl peroxide combination gel (0.1%/2.5% and 0.3%/2.5%), as well as its specific mechanisms of action that target acne vulgaris. The authors also offer an expert opinion on the use of adapalene/benzoyl peroxide gel compared with other topical therapies. Expert opinion: Adapalene/benzoyl peroxide gel is safe and highly effective in the treatment of acne vulgaris. Its efficacy, tolerability, and ease-of-use are superior to other topical acne therapies, and its use does not contribute to antibiotic resistance. However, the cost of adapalene/benzoyl peroxide gel and lack of available generics may prohibit its use.

KW - Acne vulgaris

KW - adapalene

KW - benzoyl peroxide

KW - combination therapy

KW - retinoids

KW - topical

KW - Adapalene

KW - Humans

KW - Treatment Outcome

KW - Dermatologic Agents/therapeutic use

KW - Naphthalenes

KW - Benzoyl Peroxide

KW - Acne Vulgaris/drug therapy

KW - Drug Combinations

U2 - 10.1080/14656566.2021.1939678

DO - 10.1080/14656566.2021.1939678

M3 - Journal article

C2 - 34086519

AN - SCOPUS:85107870415

SN - 1465-6566

VL - 22

SP - 1661

EP - 1667

JO - Expert Opinion on Pharmacotherapy

JF - Expert Opinion on Pharmacotherapy

IS - 13

ER -

An overview of adapalene and benzoyl peroxide once-daily topical gel as a therapeutic option for acne

Abstract

Bibliografisk note

Finansiering

Dokumenter og links

SDU link

Fingeraftryk

Citationsformater